<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40932963</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Mechanical Heart Valves: A Systematic Review.</ArticleTitle><Pagination><StartPage>e89736</StartPage><MedlinePgn>e89736</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e89736</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.89736</ELocationID><Abstract><AbstractText>Patients with mechanical heart valves require lifelong anticoagulation primarily due to the thrombogenic nature of these valves. Warfarin has been the mainstay of therapy, but its drug-drug interactions and frequent monitoring requirements have diverted attention toward DOACs (direct oral anticoagulants) such as apixaban, rivaroxaban, and dabigatran. However, the use of DOACs in this group of patients remains controversial, particularly after negative outcomes in earlier trials. This systematic review focuses on the efficacy of DOACs compared to warfarin for preventing thromboembolic events and associated bleeding risks in patients with mechanical heart valves. Most evidence comes from observational studies and meta-analyses. More limited data exist for patients with mechanical heart valves.&#xa0;We systematically searched PubMed, PubMed Central, and Google Scholar for English-language studies published between January 2015 and May 5, 2025. Eligible studies included randomized controlled trials (RCTs), observational studies, systematic reviews, and meta-analyses comparing DOACs and warfarin in adults with mechanical heart valves and related comorbidities such as atrial fibrillation and valvular heart disease. Articles were screened and assessed using standard quality appraisal tools. We included three observational studies, two RCTs, and six systematic reviews and meta-analyses.&#xa0;Most of the studies favored warfarin as the standard therapy for patients with mechanical heart valves, while DOACs showed relatively inferior outcomes. Current practice guidelines from the American College of Cardiology Foundation/American Heart Association Task Force suggest warfarin as the standard treatment for patients with mechanical heart valves. There is a further need for long-term, high-quality clinical trials using a newer generation of DOACs among this high-risk group.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, Mandefro et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mandefro</LastName><ForeName>Bethel T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundara</LastName><ForeName>Sri Vidya</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busmail</LastName><ForeName>Hamide</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weerakoon</LastName><ForeName>Sasika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avula</LastName><ForeName>Sravanthi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iftikhar</LastName><ForeName>Laraib</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medicine, California Institute of Behavioral Neurosciences &amp; Psychology, Fairfield, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coagulation inhibitors</Keyword><Keyword MajorTopicYN="N">direct oral anticoagulant (doac)</Keyword><Keyword MajorTopicYN="N">mechanical heart valve (mhv)</Keyword><Keyword MajorTopicYN="N">prosthetic heart valve</Keyword><Keyword MajorTopicYN="N">warfarin</Keyword></KeywordList><CoiStatement>Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40932963</ArticleId><ArticleId IdType="pmc">PMC12419551</ArticleId><ArticleId IdType="doi">10.7759/cureus.89736</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>How did we get here?: a historical review and critical analysis of anticoagulation therapy following mechanical valve replacement. MacIsaac S, Jaffer IH, Belley-C&#xf4;t&#xe9; EP, McClure GR, Eikelboom JW, Whitlock RP. Circulation. 2019;140:1933&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">31790297</ArticleId></ArticleIdList></Reference><Reference><Citation>iData Research: Over 290,000 heart valve replacements per year in the United States by 2029. States by.  [
Jun;
2025 
]. 2024. https://idataresearch.com/heart-valve-replacements-per-year-in-the-united-states/ https://idataresearch.com/heart-valve-replacements-per-year-in-the-united-states/</Citation></Reference><Reference><Citation>Mechanical valves: past, present, and future - a review. Leviner DB, Abraham D, Ronai T, Sharoni E. J Clin Med. 2024;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11242849</ArticleId><ArticleId IdType="pubmed">38999334</ArticleId></ArticleIdList></Reference><Reference><Citation>Optimizing age-specific outcomes after mechanical vs bioprosthetic prosthetic heart valve replacement. Otto CM. JAMA Netw Open. 2023;6:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">37213105</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticoagulants: a short history, their mechanism of action, pharmacology, and indications. Heestermans M, Poenou G, Hamzeh-Cognasse H, Cognasse F, Bertoletti L. Cells. 2022;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9600347</ArticleId><ArticleId IdType="pubmed">36291080</ArticleId></ArticleIdList></Reference><Reference><Citation>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. O'Gara PT, Kushner FG, Ascheim DD, et al. Circulation. 2013;127:0&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">23247304</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabigatran versus warfarin in patients with mechanical heart valves. Eikelboom JW, Connolly SJ, Brueckmann M, et al. N Engl J Med. 2013;369:1206&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pubmed">23991661</ArticleId></ArticleIdList></Reference><Reference><Citation>Use of direct oral anticoagulants in patients with atrial fibrillation and valvular heart lesions. Di Biase L. J Am Heart Assoc. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4802477</ArticleId><ArticleId IdType="pubmed">26892528</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;A tale of two cities&#x201d;: anticoagulation management in patients with atrial fibrillation and prosthetic valves in the era of direct oral anticoagulants. Palmiero G, Melillo E, Rubino AS. Medicina (Kaunas) 2019;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6722984</ArticleId><ArticleId IdType="pubmed">31382702</ArticleId></ArticleIdList></Reference><Reference><Citation>Off-label use of direct oral anticoagulants in patients receiving surgical mechanical and bioprosthetic heart valves. Kalra A, Raza S, Jafry BH, King HE, Lahorra JA, Svensson LG, Kapadia SR. JAMA Netw Open. 2021;4:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941196</ArticleId><ArticleId IdType="pubmed">33683332</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes of patients with a mechanical heart valve and poor anticoagulation control on warfarin. Johansson I, Benz AP, Kovalova T, et al. Thromb Haemost. 2024;124:613&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11199045</ArticleId><ArticleId IdType="pubmed">38158198</ArticleId></ArticleIdList></Reference><Reference><Citation>Direct oral anticoagulants compared with warfarin in patients with atrial fibrillation and valvular heart disease without mechanical valves. Dawwas GK, Lewis JD, Cuker A. J Am Heart Assoc. 2025;14:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12074781</ArticleId><ArticleId IdType="pubmed">39950313</ArticleId></ArticleIdList></Reference><Reference><Citation>Apixaban or warfarin in patients with an On-X mechanical aortic valve. Wang TY, Svensson LG, Wen J, et al. NEJM Evid. 2023;2:0.</Citation><ArticleIdList><ArticleId IdType="pubmed">38320162</ArticleId></ArticleIdList></Reference><Reference><Citation>Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X aortic heart valve. Jawitz OK, Wang TY, Lopes RD, et al. Am Heart J. 2020;227:91&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484170</ArticleId><ArticleId IdType="pubmed">32693197</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfarin versus direct oral anticoagulants in patients with artificial heart valves: a systematic review and meta-analysis. Srivastava Y, Deo S, Almader-Douglas D, et al.  https://www.clinicalcasereportsint.com/open-access/warfarin-versus-direct-oral-anticoagulants-in-patients-with-artificial-heart-9838.pdf Clin Case Rep Int. 2024;4:8.</Citation></Reference><Reference><Citation>Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. de Souza Lima Bitar Y, Neto MG, Filho JA, et al. Drugs R D. 2019;19:117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6544604</ArticleId><ArticleId IdType="pubmed">31055767</ArticleId></ArticleIdList></Reference><Reference><Citation>Comparing clinical outcomes of NOACs with warfarin on atrial fibrillation with valvular heart diseases: a meta-analysis. He Q, Sze CY, Shum TY, et al. BMC Cardiovasc Disord. 2019;19:113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6521383</ArticleId><ArticleId IdType="pubmed">31092194</ArticleId></ArticleIdList></Reference><Reference><Citation>Antithrombotic management after aortic valve replacement with biological prosthesis: a meta-analysis. Uimonen M, Kuitunen I, Ponkilainen V, Mennander A, Mattila MS. J Cardiothorac Surg. 2024;19:385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11202358</ArticleId><ArticleId IdType="pubmed">38926789</ArticleId></ArticleIdList></Reference><Reference><Citation>Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. J Am Heart Assoc. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5586302</ArticleId><ArticleId IdType="pubmed">28720644</ArticleId></ArticleIdList></Reference><Reference><Citation>Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. Kido K, Ghaffar YA, Lee JC, Bianco C, Shimizu M, Shiga T, Hashiguchi M. PLoS One. 2021;16:0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8177531</ArticleId><ArticleId IdType="pubmed">34086768</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40897479</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Nurse-led cardiac rehabilitation programme on physical capacity and mental health for heart valve patients: study protocol of a quasi-experimental study.</ArticleTitle><Pagination><StartPage>e096823</StartPage><MedlinePgn>e096823</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e096823</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-096823</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Evidence-based early rehabilitation intervention after heart valve surgery has been proven to have many benefits, but the experience of implementing nurse-led early rehabilitation combining exercise and psychology is still lacking. It is urgent to find a more acceptable and cost-effective method to provide exercise intervention and psychological support. The aim of this study is to design a nurse-led cardiac rehabilitation programme to increase the physical capacity and mental health for heart valve patient based on broaden-and-build theory.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">A non-blinded randomised controlled trial will be conducted. A total of 86 adults diagnosed with heart valve disease will be recruited and randomly assigned to the control group and intervention group. The recovery for valvular heart disease intervention, based on the broaden-and-build theory, will be guided one-on-one by a multidisciplinary team and will consist of two main components: physical intervention and psychological intervention. The baseline assessment will be conducted 1 to 2&#x2009;days after admission, and sequent evaluations will be implemented at post-intervention, 3 months after intervention and 6 months after intervention. The primary outcome is the finding of six-min walk test and mental state. Other outcomes include quality of life, 36-item short-form health survey, Short Physical Performance Battery, stress, coping modes and social support.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">This study was conducted following the Helsinki Declaration and was approved by the ethics committee of the Zhong Da Hospital, Southeast University (2024ZDSYLL098-P01). The results of this study are scheduled to be published in relevant peer-reviewed journals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">Registered at the Chinese Clinical Trials.gov (ChiCTR2400090853).</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhou</LastName><ForeName>Yufeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yurong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Pan</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7299-0627</Identifier><AffiliationInfo><Affiliation>Department of cardiac surgery, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China 1183180315@qq.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072038" MajorTopicYN="Y">Cardiac Rehabilitation</DescriptorName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="Y">Mental Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006349" MajorTopicYN="Y">Heart Valve Diseases</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070857" MajorTopicYN="N">Walk Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="N">Exercise Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065228" MajorTopicYN="N">Non-Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cardiothoracic surgery</Keyword><Keyword MajorTopicYN="N">Nursing Care</Keyword><Keyword MajorTopicYN="N">Valvular heart disease</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>4</Day><Hour>2</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>2</Day><Hour>21</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40897479</ArticleId><ArticleId IdType="pmc">PMC12406905</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-096823</ArticleId><ArticleId IdType="pii">bmjopen-2024-096823</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yadgir S, Johnson CO, Aboyans V, et al. Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017. Circulation. 2020;141:1670&#x2013;80. doi: 10.1161/CIRCULATIONAHA.119.043391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.043391</ArticleId><ArticleId IdType="pubmed">32223336</ArticleId></ArticleIdList></Reference><Reference><Citation>Brecker S, Mealing S, Padhiar A, et al. Cost-utility of transcatheter aortic valve implantation for inoperable patients with severe aortic stenosis treated by medical management: a UK cost-utility analysis based on patient-level data from the ADVANCE study. Open Heart. 2014;1 doi: 10.1136/openhrt-2014-000155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2014-000155</ArticleId><ArticleId IdType="pmc">PMC4207938</ArticleId><ArticleId IdType="pubmed">25349700</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchnowski P. Risk Factors of sudden cardiac arrest during the postoperative period in patient undergoing heart valve surgery. J Clin Med. 2022;11 doi: 10.3390/jcm11237098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11237098</ArticleId><ArticleId IdType="pmc">PMC9737591</ArticleId><ArticleId IdType="pubmed">36498672</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RS, Dalal HM, Zwisler AD. Cardiac rehabilitation for heart failure: &#x201c;Cinderella&#x201d; or evidence-based pillar of care? Eur Heart J. 2023;44:1511&#x2013;8. doi: 10.1093/eurheartj/ehad118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad118</ArticleId><ArticleId IdType="pmc">PMC10149531</ArticleId><ArticleId IdType="pubmed">36905176</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42:17&#x2013;96. doi: 10.1093/eurheartj/ehaa605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa605</ArticleId><ArticleId IdType="pubmed">33180902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown TM, Pack QR, Aberegg E, et al. Core components of cardiac rehabilitation programs: 2024 update: a scientific statement from the american heart association and the american association of cardiovascular and pulmonary rehabilitation. Circulation. 2024;150:e328&#x2013;47. doi: 10.1161/CIR.0000000000001289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001289</ArticleId><ArticleId IdType="pubmed">39315436</ArticleId></ArticleIdList></Reference><Reference><Citation>Molloy CD, Long L, Mordi IR, et al. Exercise-based cardiac rehabilitation for adults with heart failure - 2023 Cochrane systematic review and meta-analysis. Eur J Heart Fail. 2023;25:2263&#x2013;73. doi: 10.1002/ejhf.3046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.3046</ArticleId><ArticleId IdType="pubmed">37850321</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor RS, Fredericks S, Jones I, et al. Global perspectives on heart disease rehabilitation and secondary prevention: a scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation. Eur Heart J. 2023;44:2515&#x2013;25. doi: 10.1093/eurheartj/ehad225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad225</ArticleId><ArticleId IdType="pmc">PMC10361025</ArticleId><ArticleId IdType="pubmed">37477626</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi W, Green H, Sikhosana N, et al. Effectiveness of telehealth cardiac rehabilitation programs on health outcomes of patients with coronary heart diseases: an umbrella review. J Cardiopulm Rehabil Prev . 2024;44:15&#x2013;25. doi: 10.1097/HCR.0000000000000807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HCR.0000000000000807</ArticleId><ArticleId IdType="pubmed">37335820</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z, Qin N, Shi S, et al. Knowledge, attitude, and practice of cardiac rehabilitation referral among healthcare professionals in China: a mediation model. Prev Med Rep. 2025;53 doi: 10.1016/j.pmedr.2025.103064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pmedr.2025.103064</ArticleId><ArticleId IdType="pmc">PMC12008619</ArticleId><ArticleId IdType="pubmed">40256408</ArticleId></ArticleIdList></Reference><Reference><Citation>Coffey S, Roberts-Thomson R, Brown A, et al. Global epidemiology of valvular heart disease. Nat Rev Cardiol. 2021;18:853&#x2013;64. doi: 10.1038/s41569-021-00570-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-021-00570-z</ArticleId><ArticleId IdType="pubmed">34172950</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez KS, Dwyer AA, Ramelet AS. International practice settings, interventions and outcomes of nurse practitioners in geriatric care: A scoping review. Int J Nurs Stud. 2018;78:61&#x2013;75. doi: 10.1016/j.ijnurstu.2017.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijnurstu.2017.09.010</ArticleId><ArticleId IdType="pubmed">28964502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang Y, Chen Y, et al. Nurse-led motor function rehabilitation program for acute ischemic stroke: a randomized pilot study. J Nurs Res. 2022;30 doi: 10.1097/jnr.0000000000000529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/jnr.0000000000000529</ArticleId><ArticleId IdType="pubmed">36445316</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges MGB, Borges DL, Ribeiro MO, et al. Early mobilization prescription in patients undergoing cardiac surgery: systematic review. Braz J Cardiovasc Surg. 2022;37:227&#x2013;38. doi: 10.21470/1678-9741-2021-0140.</Citation><ArticleIdList><ArticleId IdType="doi">10.21470/1678-9741-2021-0140</ArticleId><ArticleId IdType="pmc">PMC9054150</ArticleId><ArticleId IdType="pubmed">35244377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, You X, Lin Y, et al. A systematic review and meta-analysis of the effects of early mobilization therapy in patients after cardiac surgery. Medicine (Baltimore) 2020;99 doi: 10.1097/MD.0000000000018843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000018843</ArticleId><ArticleId IdType="pmc">PMC7004682</ArticleId><ArticleId IdType="pubmed">31977881</ArticleId></ArticleIdList></Reference><Reference><Citation>Yayla A, &#xd6;zer N. Effects of early mobilization protocol performed after cardiac surgery on patient care outcomes. Int J Nurs Pract. 2019;25 doi: 10.1111/ijn.12784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijn.12784</ArticleId><ArticleId IdType="pubmed">31617651</ArticleId></ArticleIdList></Reference><Reference><Citation>Awaludin S, Novitasari D. Determinants of early mobilization in postcardiac surgery patients. Curr Probl Cardiol. 2024;49:102110. doi: 10.1016/j.cpcardiol.2023.102110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2023.102110</ArticleId><ArticleId IdType="pubmed">37769754</ArticleId></ArticleIdList></Reference><Reference><Citation>Holdgaard A, Eckhardt-Hansen C, Lund T, et al. Intensive group-based cognitive therapy in patients with cardiac disease and psychological distress-a randomized controlled trial protocol. Trials. 2021;22 doi: 10.1186/s13063-021-05405-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-021-05405-3</ArticleId><ArticleId IdType="pmc">PMC8283384</ArticleId><ArticleId IdType="pubmed">34271952</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakar E, Billar RJ, van Rosmalen J, et al. Music intervention to relieve anxiety and pain in adults undergoing cardiac surgery: a systematic review and meta-analysis. Open Heart. 2021;8 doi: 10.1136/openhrt-2020-001474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001474</ArticleId><ArticleId IdType="pmc">PMC7839877</ArticleId><ArticleId IdType="pubmed">33495383</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay SS, Croghan IT, Bauer BA. Mitigating preoperative anxiety in cardiac surgery patients through virtual reality: a novel approach. Mayo Clin Proc. 2025;100:184&#x2013;6. doi: 10.1016/j.mayocp.2024.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2024.12.003</ArticleId><ArticleId IdType="pubmed">39909666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibilitz KL, Berg SK, Rasmussen TB, et al. Cardiac rehabilitation increases physical capacity but not mental health after heart valve surgery: a randomised clinical trial. Heart. 2016;102:1995&#x2013;2003. doi: 10.1136/heartjnl-2016-309414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2016-309414</ArticleId><ArticleId IdType="pubmed">27492941</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Zhu C, Chen S, et al. Exercise-based cardiac rehabilitation for patients after heart valve surgery: a systematic review and re-evaluation with evidence mapping study. Clin Cardiol. 2025;48 doi: 10.1002/clc.70117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.70117</ArticleId><ArticleId IdType="pmc">PMC11934209</ArticleId><ArticleId IdType="pubmed">40130747</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham LN, Sibilitz KL, Berg SK, et al. Exercise-based cardiac rehabilitation for adults after heart valve surgery. Cochrane Database Syst Rev. 2021;5 doi: 10.1002/14651858.CD010876.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD010876.pub3</ArticleId><ArticleId IdType="pmc">PMC8105032</ArticleId><ArticleId IdType="pubmed">33962483</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredrickson BL. The broaden-and-build theory of positive emotions. Philos Trans R Soc Lond B Biol Sci . 2004;359:1367&#x2013;78. doi: 10.1098/rstb.2004.1512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2004.1512</ArticleId><ArticleId IdType="pmc">PMC1693418</ArticleId><ArticleId IdType="pubmed">15347528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 Statement: defining standard protocol items for clinical trials. Rev Panam Salud Publica. 2015;38:506&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114122</ArticleId><ArticleId IdType="pubmed">27440100</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2012;10:28&#x2013;55. doi: 10.1016/j.ijsu.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2011.10.001</ArticleId><ArticleId IdType="pubmed">22036893</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Liu L, Liu C, et al. Effects of preoperative cardiac rehabilitation nursing intervention for patients with advanced valvular heart disease on cardiac function and quality of life. Chin J Nurs. 2019;25:2324&#x2013;7. doi: 10.3760/cma.j.issn.1674-2907.2019.18.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1674-2907.2019.18.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Society AT. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111&#x2013;7. doi: 10.1164/ajrccm.166.1.at1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.166.1.at1102</ArticleId><ArticleId IdType="pubmed">12091180</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361&#x2013;70. doi: 10.1111/j.1600-0447.1983.tb09716.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0447.1983.tb09716.x</ArticleId><ArticleId IdType="pubmed">6880820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye W JX. Chinese Journal of Behavioral Medicine and Brain Science. 1993. Application and evaluation of &#x201c;general hospital anxiety and depression scale&#x201d; in general hospital patients.</Citation></Reference><Reference><Citation>Ware JE, Jr Sherbourne CD. The MOS 36-ltem short-form health survey (SF-36) Med Care. 1992;30:473&#x2013;83. doi: 10.1097/00005650-199206000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199206000-00002</ArticleId><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">6668417</ArticleId></ArticleIdList></Reference><Reference><Citation>Feifel H, Strack S, Nagy VT. Coping strategies and associated features of medically ill patients. Psychosom Med. 1987;49:616&#x2013;25. doi: 10.1097/00006842-198711000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-198711000-00007</ArticleId><ArticleId IdType="pubmed">3423168</ArticleId></ArticleIdList></Reference><Reference><Citation>S X. Theoretical basis and research application of social support rating scale. J Clin Psychiatry. 1994;2:98&#x2013;100.</Citation></Reference><Reference><Citation>Bhagat R, Bojarski L, Chevalier S, et al. Quality tolerance limits: framework for successful implementation in clinical development. Ther Innov Regul Sci. 2021;55:251&#x2013;61. doi: 10.1007/s43441-020-00209-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43441-020-00209-0</ArticleId><ArticleId IdType="pmc">PMC7864825</ArticleId><ArticleId IdType="pubmed">32885397</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Xu H. The development of cardiac rehabilitation in china: current status and future perspectives. Rev Cardiovasc Med. 2024;25 doi: 10.31083/j.rcm2507233.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.rcm2507233</ArticleId><ArticleId IdType="pmc">PMC11317330</ArticleId><ArticleId IdType="pubmed">39139407</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou V, Xanthopoulos A, Giamouzis G, et al. Efficacy, efficiency and safety of a cardiac telerehabilitation programme using wearable sensors in patients with coronary heart disease: the TELEWEAR-CR study protocol. BMJ Open. 2022;12 doi: 10.1136/bmjopen-2021-059945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-059945</ArticleId><ArticleId IdType="pmc">PMC9226468</ArticleId><ArticleId IdType="pubmed">35738643</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou V, Kapreli E, Davos CH, et al. Safety and long-term outcomes of remote cardiac rehabilitation in coronary heart disease patients: A systematic review. Digit Health. 2024;10 doi: 10.1177/20552076241237661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20552076241237661</ArticleId><ArticleId IdType="pmc">PMC10964460</ArticleId><ArticleId IdType="pubmed">38533308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennis S, Lobley G, Worrall S, et al. Effectiveness and safety of early initiation of poststernotomy cardiac rehabilitation exercise training: the SCAR randomized clinical trial. JAMA Cardiol. 2022;7:817&#x2013;24. doi: 10.1001/jamacardio.2022.1651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.1651</ArticleId><ArticleId IdType="pmc">PMC9218928</ArticleId><ArticleId IdType="pubmed">35731506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40888584</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9645</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>European heart journal</Title><ISOAbbreviation>Eur Heart J</ISOAbbreviation></Journal><ArticleTitle>Surgical left atrial appendage occlusion in valvular heart disease without atrial fibrillation: the OPINION trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ehaf674</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/eurheartj/ehaf674</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">While surgical left atrial appendage occlusion (SLAAO) reduces stroke in atrial fibrillation (AF) patients, its efficacy in patients without pre-operative AF but with CHA&#x2082;DS&#x2082;-VASc &#x2265;2 remains uncertain despite their high post-operative AF risk (15-54%). The aim of this study was to evaluate whether prophylactic SLAAO reduces post-operative thrombo-embolic events in valvular surgery patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The OPINION was a multicentre, open-label, randomized, superiority trial conducted at three cardiac surgery centres in China. Eligible non-AF patients with CHA&#x2082;DS&#x2082;-VASc &#x2265;2 and an indication for valve repair or replacement due to mitral or aortic valve lesions were randomly assigned (1:1) to undergo SLAAO (intervention arm) or not undergo SLAAO (control arm) during surgery. The primary outcome was a composite of ischaemic stroke, transient ischaemic attack (TIA), or cardiovascular mortality assessed at 1 year. The primary analysis was done in the intention-to-treat population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between April 2021 and June 2024, a total of 2157 patients were enrolled and randomized. After exclusion of 39 patients who withdrew informed consent, 2118 participants were included in the intention-to-treat population (1062 in the SLAAO group and 1056 in the control group). Baseline characteristics were well-balanced between the SLAAO group and control group (mean age 55.5 [11.4] vs 55.6 [11.5] years, P = .65; female 32.9% vs 32.3%, P = .78; CHA2DS2-VASc score 2.88 [0.98] vs 2.87 [0.96], P = .83; median EuroSCORE II 1.58% [1.42%] vs 1.56% [1.28%], P = .74). The 1-year primary endpoint occurred in 73 (6.9%) patients in the SLAAO group and in 87 (8.2%) patients in the control group (hazard ratio 0.83; 95% confidence interval 0.61-1.14; P = .25).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">For valvular surgery patients with CHA&#x2082;DS&#x2082;-VASc scores &#x2265;2 but no pre-operative AF, routine prophylactic left atrial appendage closure did not significantly reduce the incidence of the primary composite endpoint (ischaemic stroke, TIA, and cardiovascular mortality) at 1-year follow-up.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ChiCTR.org registry ChiCTR2100042238.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ju</LastName><ForeName>Fan</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5066-0013</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Hengchao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yanyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Research and Biometrics Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8929-7178</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xianqiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Junming</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6919-9164</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Pixiong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing 100020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-1157-8302</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Research and Biometrics Centre, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Hansong</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7775-1510</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, No. 167 North Lishi Road, Xicheng District, Beijing 100037, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Beijing Municipal Science &amp; Technology Commission</Agency><Country/></Grant><Grant><GrantID>Z201100005520033</GrantID><Agency>Clinical Diagnosis and Treatment Techniques</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Heart J</MedlineTA><NlmUniqueID>8006263</NlmUniqueID><ISSNLinking>0195-668X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">CHA&#x2082;DS&#x2082;-VASc score</Keyword><Keyword MajorTopicYN="N">Surgical left atrial appendage occlusion</Keyword><Keyword MajorTopicYN="N">Thromboembolism</Keyword><Keyword MajorTopicYN="N">Valvular heart disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>16</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40888584</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaf674</ArticleId><ArticleId IdType="pii">8244401</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40819859</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>16</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Rationale and design of SCOPE trial: a prospective, multicentre, open-label, randomised controlled trial to evaluate the overall efficacy and safety of a <i>s</i>hort-term anticoagulation strategy versus <i>co</i>nventional single antiplatelet therapy in patients with severe aortic stenosis without indications for anticoagulation or dual antiplatelet therapy <i>p</i>ost-transcatheter aortic valve r<i>e</i>placement.</ArticleTitle><Pagination><StartPage>e098551</StartPage><MedlinePgn>e098551</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e098551</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-098551</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">While transcatheter aortic valve replacement (TAVR) has become a well-established standard of care for patients with symptomatic severe aortic stenosis, the optimal antithrombotic strategy post-TAVR remains a subject of debate, particularly in patients without clear indications for anticoagulation or dual antiplatelet therapy. This study aims to investigate the safety and efficacy of rivaroxaban compared with antiplatelet monotherapy in this specific patient population.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">This study is designed as a prospective, multicentre, open-label, randomised controlled trial. A total of 454 patients, who have successfully undergone TAVR and do not have indications for long-term anticoagulation or dual antiplatelet therapy, will be consecutively enrolled from seven centres across China. Participants will be randomly assigned to receive either anticoagulation with rivaroxaban (20/15&#x2009;mg) or conventional antiplatelet therapy (aspirin or clopidogrel) for 1&#x2009;month. Follow-up evaluations are scheduled at 1, 3, 6 and 12 months post-procedure. After the initial 1-month antithrombotic therapy, the regimen may be adjusted by the investigator based on the patient's clinical and imaging follow-up results. The primary endpoint is a hierarchical composite of cardiovascular death, first occurrence of myocardial infarction or stroke, first occurrence of life-threatening, disabling or major bleeding, and grade 3 or higher hypo-attenuated leaflet thickening and reduced leaflet motion at 12 months post-TAVR. The win ratio method will be employed to analyse the primary endpoint.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">This trial was approved by the Ethics Committee of the Beijing AnZhen Hospital. All relevant results will be disseminated through publications in peer-reviewed journals and presentations at conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">ChiCTR2400087453.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yan</LastName><ForeName>Yunfeng</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-1814-5019</Identifier><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6973-1333</Identifier><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ran</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5025-0927</Identifier><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lihua</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xinmin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhengming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Taiyang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Zhinan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5040-2492</Identifier><AffiliationInfo><Affiliation>Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yingxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Research and Biometrics Center, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yi-Da</ForeName><Initials>YD</Initials><Identifier Source="ORCID">0000-0003-0861-5803</Identifier><AffiliationInfo><Affiliation>Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Huiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Cardiology Department, Beijing Hospital, National Center of Gerontology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Tangdu Hospital, Airforce Medical University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Liang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, The First Hospital of China Medical University, Shenyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pocock</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>EPH, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Guangyuan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-7868-6132</Identifier><AffiliationInfo><Affiliation>Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China songgy_anzhen@VIP.163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Investigators</LastName><ForeName>Scope</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9NDF7JZ4M3</RegistryNumber><NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>R16CO5Y76E</RegistryNumber><NameOfSubstance UI="D001241">Aspirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>A74586SNO7</RegistryNumber><NameOfSubstance UI="D000077144">Clopidogrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001024" MajorTopicYN="Y">Aortic Valve Stenosis</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065467" MajorTopicYN="Y">Transcatheter Aortic Valve Replacement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010975" MajorTopicYN="Y">Platelet Aggregation Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069552" MajorTopicYN="Y">Rivaroxaban</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="Y">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077144" MajorTopicYN="N">Clopidogrel</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="Y">Factor Xa Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anticoagulation</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword><Keyword MajorTopicYN="N">Valvular heart disease</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>17</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40819859</ArticleId><ArticleId IdType="pmc">PMC12359410</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-098551</ArticleId><ArticleId IdType="pii">bmjopen-2024-098551</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72&#x2013;227. doi: 10.1161/CIR.0000000000000923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000923</ArticleId><ArticleId IdType="pubmed">33332150</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561&#x2013;632. doi: 10.1093/eurheartj/ehab395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Makkar RR, Fontana G, Jilaihawi H, et al. Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med. 2015;373:2015&#x2013;24. doi: 10.1056/NEJMoa1509233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1509233</ArticleId><ArticleId IdType="pubmed">26436963</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarty T, S&#xf8;ndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383. doi: 10.1016/S0140-6736(17)30757-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30757-2</ArticleId><ArticleId IdType="pubmed">28330690</ArticleId></ArticleIdList></Reference><Reference><Citation>Egbe AC, Pislaru SV, Pellikka PA, et al. Bioprosthetic Valve Thrombosis Versus Structural Failure: Clinical and Echocardiographic Predictors. J Am Coll Cardiol. 2015;66:2285&#x2013;94. doi: 10.1016/j.jacc.2015.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.09.022</ArticleId><ArticleId IdType="pubmed">26610876</ArticleId></ArticleIdList></Reference><Reference><Citation>Jilaihawi H, Asch FM, Manasse E, et al. Systematic CT Methodology for the Evaluation of Subclinical Leaflet Thrombosis. JACC Cardiovasc Imaging. 2017;10:461&#x2013;70. doi: 10.1016/j.jcmg.2017.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2017.02.005</ArticleId><ArticleId IdType="pubmed">28385256</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanke P, Leipsic JA, Popma JJ, et al. Bioprosthetic Aortic Valve Leaflet Thickening in the Evolut Low Risk Sub-Study. J Am Coll Cardiol. 2020;75:2430&#x2013;42. doi: 10.1016/j.jacc.2020.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.022</ArticleId><ArticleId IdType="pubmed">32234463</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose J, Sulimov DS, El-Mawardy M, et al. Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. JACC Cardiovasc Interv. 2017;10:686&#x2013;97. doi: 10.1016/j.jcin.2017.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2017.01.045</ArticleId><ArticleId IdType="pubmed">28385406</ArticleId></ArticleIdList></Reference><Reference><Citation>Capodanno D, Petronio AS, Prendergast B, et al. Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur J Cardiothorac Surg. 2017;52:408&#x2013;17. doi: 10.1093/ejcts/ezx244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezx244</ArticleId><ArticleId IdType="pubmed">28874031</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalescot G, Redheuil A, Vincent F, et al. Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy. JACC Cardiovasc Interv. 2022;15:1794&#x2013;804. doi: 10.1016/j.jcin.2022.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2022.07.014</ArticleId><ArticleId IdType="pubmed">36137682</ArticleId></ArticleIdList></Reference><Reference><Citation>De Backer O, Dangas GD, Jilaihawi H, et al. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020;382:130&#x2013;9. doi: 10.1056/NEJMoa1911426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911426</ArticleId><ArticleId IdType="pubmed">31733182</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri R, Auffret V, Rod&#xe9;s-Cabau J. Bioprosthetic Valve Thrombosis. J Am Coll Cardiol. 2017;69:2193&#x2013;211. doi: 10.1016/j.jacc.2017.02.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.02.051</ArticleId><ArticleId IdType="pubmed">28449781</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangas GD, Tijssen JGP, W&#xf6;hrle J, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020;382:120&#x2013;9. doi: 10.1056/NEJMoa1911425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911425</ArticleId><ArticleId IdType="pubmed">31733180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020;383:1447&#x2013;57. doi: 10.1056/NEJMoa2017815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2017815</ArticleId><ArticleId IdType="pubmed">32865376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato Y, Torii S, Kawai K, et al. TCT-325 Pathology of Hypo-Attenuated Leaflet Thickening (HALT) in CoreValve/Evolut Self-expanding Transcatheter Aortic Valve Bioprostheses. J Am Coll Cardiol. 2022;80:B130. doi: 10.1016/j.jacc.2022.08.380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.08.380</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang MH, Ahn J-M, Kang D-Y, et al. Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement. Heart. 2023;110:140&#x2013;7. doi: 10.1136/heartjnl-2023-322946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2023-322946</ArticleId><ArticleId IdType="pubmed">37586823</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner-Gager GM, Rogozarski J, Kronberger C, et al. Prediction model for leaflet thrombosis in patients undergoing transcatheter aortic valve implantation: the EFFORT study. Clin Res Cardiol. 2024 doi: 10.1007/s00392-024-02486-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-024-02486-3</ArticleId><ArticleId IdType="pubmed">39012508</ArticleId></ArticleIdList></Reference><Reference><Citation>Adrichem R, Rodes Cabau J, Mehran R, et al. Treatment of Transcatheter Aortic Valve Thrombosis. J Am Coll Cardiol. 2024;84:848&#x2013;61. doi: 10.1016/j.jacc.2024.05.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.05.064</ArticleId><ArticleId IdType="pubmed">39168571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kappetein AP, Head SJ, G&#xe9;n&#xe9;reux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438&#x2013;54. doi: 10.1016/j.jacc.2012.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2012.09.001</ArticleId><ArticleId IdType="pubmed">23036636</ArticleId></ArticleIdList></Reference><Reference><Citation>VARC-3 WRITING COMMITTEE. G&#xe9;n&#xe9;reux P, Piazza N, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. Eur Heart J. 2021;42:1825&#x2013;57. doi: 10.1093/eurheartj/ehaa799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa799</ArticleId><ArticleId IdType="pubmed">33871579</ArticleId></ArticleIdList></Reference><Reference><Citation>Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43:2783&#x2013;97. doi: 10.1093/eurheartj/ehac242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac242</ArticleId><ArticleId IdType="pubmed">35583186</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D-W, Ahn J-M, Kang D-Y, et al. Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial. Circulation. 2022;146:466&#x2013;79. doi: 10.1161/CIRCULATIONAHA.122.059512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.122.059512</ArticleId><ArticleId IdType="pubmed">35373583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33:176&#x2013;82. doi: 10.1093/eurheartj/ehr352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr352</ArticleId><ArticleId IdType="pubmed">21900289</ArticleId></ArticleIdList></Reference><Reference><Citation>Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J. 2020;41:4391&#x2013;9. doi: 10.1093/eurheartj/ehaa665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa665</ArticleId><ArticleId IdType="pubmed">32901285</ArticleId></ArticleIdList></Reference><Reference><Citation>Garot P, Morice M-C, Angiolillo DJ, et al. Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document. EuroIntervention. 2024;20:536&#x2013;50. doi: 10.4244/EIJ-D-23-01020.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJ-D-23-01020</ArticleId><ArticleId IdType="pmc">PMC11067726</ArticleId><ArticleId IdType="pubmed">38726720</ArticleId></ArticleIdList></Reference><Reference><Citation>Rod&#xe9;s-Cabau J, Masson J-B, Welsh RC, et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv. 2017;10:1357&#x2013;65. doi: 10.1016/j.jcin.2017.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2017.04.014</ArticleId><ArticleId IdType="pubmed">28527771</ArticleId></ArticleIdList></Reference><Reference><Citation>Overtchouk P, Guedeney P, Rouanet S, et al. Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. J Am Coll Cardiol. 2019;73:13&#x2013;21. doi: 10.1016/j.jacc.2018.08.1045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.08.1045</ArticleId><ArticleId IdType="pubmed">30153483</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Trigo M, Mu&#xf1;oz-Garcia AJ, Wijeysundera HC, et al. Incidence, Timing, and Predictors of Valve Hemodynamic Deterioration After Transcatheter Aortic Valve Replacement: Multicenter Registry. J Am Coll Cardiol. 2016;67:644&#x2013;55. doi: 10.1016/j.jacc.2015.10.097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.10.097</ArticleId><ArticleId IdType="pubmed">26868689</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40533205</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Benefits of heart valve clinics for patients: a systematic review.</ArticleTitle><Pagination><StartPage>e096538</StartPage><MedlinePgn>e096538</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e096538</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-096538</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the impact of heart valve clinics (HVCs) versus standard of care (SOC) on disease detection, timing of intervention and clinical outcomes in patients with valvular heart disease (VHD).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in PROSPERO (CRD42024518787).</AbstractText><AbstractText Label="DATA SOURCES" NlmCategory="METHODS">PubMed, Embase, Web of Science, Scopus and the Cochrane Library from inception to 1 May 2025.</AbstractText><AbstractText Label="ELIGIBILITY CRITERIA" NlmCategory="METHODS">Randomised controlled trials or cohort studies comparing patients managed in HVCs with those receiving SOC, and reporting on outcomes such as mortality, cardiac events, time to symptom reporting or symptom severity. Studies were excluded if they lacked detailed HVC protocols, single-arm designs or were published as abstracts only.</AbstractText><AbstractText Label="DATA EXTRACTION AND SYNTHESIS" NlmCategory="METHODS">Two reviewers independently screened titles, abstracts and full texts, with discrepancies resolved by a senior adjudicator. The Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias. Meta-analysis was not conducted due to heterogeneity among studies.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three high-quality prospective cohort studies (N=1082) were included. Two studies reported mortality and cardiac events: one, a before-and-after controlled trial (n=382), recorded 11 deaths in the HVC group; the other reported 4 deaths in the HVC group (n=156) versus 17 deaths in the SOC group (n=156) (p&lt;0.05). Additionally, two studies found that HVCs significantly reduced the interval between symptom onset and reporting (p&lt;0.05), as well as the proportion of patients presenting with severe symptoms (defined as New York Heart Association (NYHA) class or Canadian Cardiovascular Society (CCS) class &#x2265;III).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">HVCs facilitate stratified and precise management of the whole-life cycle of patients with VHD, enhancing early detection and referral, and leading to reduced mortality and major cardiac events compared with SOC.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ran</LastName><ForeName>Zechao</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0009-0002-9445-4179</Identifier><AffiliationInfo><Affiliation>Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuqiang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0065-2004</Identifier><AffiliationInfo><Affiliation>Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Tingqian</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Integrated Care Management Center, Outpatient Department, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Siyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yingqiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China drguoyq@wchscu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006349" MajorTopicYN="Y">Heart Valve Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059039" MajorTopicYN="Y">Standard of Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Quality in health care</Keyword><Keyword MajorTopicYN="N">Systematic Review</Keyword><Keyword MajorTopicYN="N">Valvular heart disease</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>19</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>18</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40533205</ArticleId><ArticleId IdType="pmc">PMC12182144</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-096538</ArticleId><ArticleId IdType="pii">bmjopen-2024-096538</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet . 2006;368:1005&#x2013;11. doi: 10.1016/S0140-6736(06)69208-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69208-8</ArticleId><ArticleId IdType="pubmed">16980116</ArticleId></ArticleIdList></Reference><Reference><Citation>Messika-Zeitoun D, Baumgartner H, Burwash IG, et al. Unmet needs in valvular heart disease. Eur Heart J. 2023;44:1862&#x2013;73. doi: 10.1093/eurheartj/ehad121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehad121</ArticleId><ArticleId IdType="pubmed">36924203</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao T, Liu X, et al. A New Benchmark for Modern Management of Valvular Heart Disease: The Whole-Life Cycle Management System. JACC Asia. 2025;5:609&#x2013;32. doi: 10.1016/j.jacasi.2025.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacasi.2025.01.017</ArticleId><ArticleId IdType="pmc">PMC12081237</ArticleId><ArticleId IdType="pubmed">40202473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaede L, Di Bartolomeo R, van der Kley F, et al. Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over. EuroIntervention. 2016;12:883&#x2013;9. doi: 10.4244/EIJY16M06_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.4244/EIJY16M06_02</ArticleId><ArticleId IdType="pubmed">27283409</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37:3515&#x2013;22. doi: 10.1093/eurheartj/ehw229.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw229</ArticleId><ArticleId IdType="pmc">PMC5216199</ArticleId><ArticleId IdType="pubmed">27354049</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberszac R, Lancellotti P, Gilon D, et al. Role of a heart valve clinic programme in the management of patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2017;18:138&#x2013;44. doi: 10.1093/ehjci/jew133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/jew133</ArticleId><ArticleId IdType="pubmed">27520802</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Liu Q, Cao K, et al. Distribution, Characteristics, and Management of Older Patients With Valvular Heart Disease in China: China-DVD Study. JACC Asia . 2022;2:354&#x2013;65. doi: 10.1016/j.jacasi.2021.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacasi.2021.11.013</ArticleId><ArticleId IdType="pmc">PMC9627799</ArticleId><ArticleId IdType="pubmed">36338396</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaour B, Menexi C, Shah BN. Clinical and echocardiographic follow-up of patients following surgical heart valve repair or replacement: a tertiary centre experience. Echo Res Pract. 2018;5:113&#x2013;9. doi: 10.1530/ERP-18-0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERP-18-0035</ArticleId><ArticleId IdType="pmc">PMC6107756</ArticleId><ArticleId IdType="pubmed">29976783</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancellotti P, Rosenhek R, Pibarot P, et al. ESC Working Group on Valvular Heart Disease position paper--heart valve clinics: organization, structure, and experiences. Eur Heart J. 2013;34:1597&#x2013;606. doi: 10.1093/eurheartj/ehs443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehs443</ArticleId><ArticleId IdType="pubmed">23293304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JB. Specialist valve clinic: why, who and how? Heart. 2019;105:1913&#x2013;20. doi: 10.1136/heartjnl-2019-315203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-315203</ArticleId><ArticleId IdType="pubmed">31784475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S, Parkin D, Pearce K. Educational series on the specialist valve clinic: What is a valve clinic? Echo Res Pract. 2019;6:T7&#x2013;13. doi: 10.1530/ERP-18-0086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERP-18-0086</ArticleId><ArticleId IdType="pmc">PMC6865861</ArticleId><ArticleId IdType="pubmed">31082801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancellotti P, Rosenhek R, Pibarot P. Heart valve clinic: rationale and organization. Can J Cardiol. 2014;30:1104&#x2013;7. doi: 10.1016/j.cjca.2014.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2014.01.019</ArticleId><ArticleId IdType="pubmed">24841083</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561&#x2013;632. doi: 10.1093/eurheartj/ehab395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab395</ArticleId><ArticleId IdType="pubmed">34453165</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers&#x2019; to authors&#x2019; assessments. BMC Med Res Methodol. 2014;14:45. doi: 10.1186/1471-2288-14-45.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-45</ArticleId><ArticleId IdType="pmc">PMC4021422</ArticleId><ArticleId IdType="pubmed">24690082</ArticleId></ArticleIdList></Reference><Reference><Citation>Taggu W, Topham A, Hart L, et al. A cardiac sonographer led follow up clinic for heart valve disease. Int J Cardiol. 2009;132:240&#x2013;3. doi: 10.1016/j.ijcard.2007.11.076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2007.11.076</ArticleId><ArticleId IdType="pubmed">18255174</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolisso P, Beles M, Belmonte M, et al. Outcomes in patients with moderate and asymptomatic severe aortic stenosis followed up in heart valve clinics. Heart. 2023;109:634&#x2013;42. doi: 10.1136/heartjnl-2022-321874.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2022-321874</ArticleId><ArticleId IdType="pubmed">36598073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberszac R, Heinze G, Binder T, et al. Long-Term Outcome of Active Surveillance in Severe But Asymptomatic Primary Mitral Regurgitation. JACC Cardiovasc Imaging. 2018;11:1213&#x2013;21. doi: 10.1016/j.jcmg.2018.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2018.05.014</ArticleId><ArticleId IdType="pubmed">30031699</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics. JAMA Cardiol. 2018;3:1060&#x2013;8. doi: 10.1001/jamacardio.2018.3152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2018.3152</ArticleId><ArticleId IdType="pmc">PMC6583052</ArticleId><ArticleId IdType="pubmed">30285058</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz-Greener G, Masih S, Fang J, et al. Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement: A Population-Based Study. Circulation. 2018;138:483&#x2013;93. doi: 10.1161/CIRCULATIONAHA.117.033432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.033432</ArticleId><ArticleId IdType="pubmed">29511000</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvidal P, Bergstr&#xf6;m R, H&#xf6;rte LG, et al. Observed and relative survival after aortic valve replacement. J Am Coll Cardiol. 2000;35:747&#x2013;56. doi: 10.1016/s0735-1097(99)00584-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0735-1097(99)00584-7</ArticleId><ArticleId IdType="pubmed">10716479</ArticleId></ArticleIdList></Reference><Reference><Citation>Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714&#x2013;20. doi: 10.1093/eurheartj/ehi471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehi471</ArticleId><ArticleId IdType="pubmed">16141261</ArticleId></ArticleIdList></Reference><Reference><Citation>Messika-Zeitoun D, Candolfi P, Vahanian A, et al. Dismal Outcomes and High Societal Burden of Mitral Valve Regurgitation in France in the Recent Era: A Nationwide Perspective. J Am Heart Assoc. 2020;9:e016086. doi: 10.1161/JAHA.120.016086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.016086</ArticleId><ArticleId IdType="pmc">PMC7792268</ArticleId><ArticleId IdType="pubmed">32696692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavone N, Burzotta F, Bruno P, et al. Heart Valve Critical Pathway and Heart Valve Clinic: Novel Benchmarks for Modern Management of Valvular Heart Disease. Crit Pathw Cardiol. 2021;20:126&#x2013;33. doi: 10.1097/HPC.0000000000000260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HPC.0000000000000260</ArticleId><ArticleId IdType="pubmed">33813534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JB, Prendergast B, Iung B, et al. Standards defining a &#x201c;Heart Valve Centre&#x201d;: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart J. 2017;38:2177&#x2013;83. doi: 10.1093/eurheartj/ehx370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx370</ArticleId><ArticleId IdType="pubmed">28838053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JB, Lancellotti P. Heart Valve Clinics, Centers, and Networks. Cardiol Clin. 2020;38:65&#x2013;74. doi: 10.1016/j.ccl.2019.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccl.2019.09.006</ArticleId><ArticleId IdType="pubmed">31753178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Cao T, Shi J, et al. Design and Application of Comprehensive Management System For Patients with Chronic Aortic Valve Disease-A Perspective From West China Hospital. Curr Probl Cardiol. 2024;49:S0146-2806(23)00586-8. doi: 10.1016/j.cpcardiol.2023.102169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2023.102169</ArticleId><ArticleId IdType="pubmed">37871710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JB, Parkin D, Rimington H, et al. Specialist valve clinic in a cardiac centre: 10-year experience. Open Heart. 2020;7:e001262. doi: 10.1136/openhrt-2020-001262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2020-001262</ArticleId><ArticleId IdType="pmc">PMC7204551</ArticleId><ArticleId IdType="pubmed">32399252</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkin D, Chambers JB. Routine follow-up for patients with prosthetic valves: the value of a nurse-led valve clinic. Br J Cardiol . 2012;19:76. doi: 10.5837/bjc.2012.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.5837/bjc.2012.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers JB, Lloyd G, Rimington HM. Multi-disciplinary valve clinics with devolved surveillance: a two-year audit. Br J Cardiol . 2011;18:231. doi: 10.5837/bjc.2011.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.5837/bjc.2011.004</ArticleId></ArticleIdList></Reference><Reference><Citation>McLachlan A, Sutton T, Ding P, et al. A Nurse Practitioner Clinic: A Novel Approach to Supporting Patients Following Heart Valve Surgery. Heart Lung Circ. 2015;24:1126&#x2013;33. doi: 10.1016/j.hlc.2015.04.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2015.04.064</ArticleId><ArticleId IdType="pubmed">25991391</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson DR, Quinn T, Stewart S. Effective nurse-led interventions in heart disease. Int J Cardiol. 2002;83:233&#x2013;7. doi: 10.1016/s0167-5273(02)00064-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0167-5273(02)00064-5</ArticleId><ArticleId IdType="pubmed">12036527</ArticleId></ArticleIdList></Reference><Reference><Citation>Grange J. The role of nurses in the management of heart failure. Heart. 2005;91 Suppl 2:ii39&#x2013;42. doi: 10.1136/hrt.2005.062117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.2005.062117</ArticleId><ArticleId IdType="pmc">PMC1876347</ArticleId><ArticleId IdType="pubmed">15831611</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CE, Smith LFP, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995. doi: 10.1136/bmj.c3995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c3995</ArticleId><ArticleId IdType="pmc">PMC2926309</ArticleId><ArticleId IdType="pubmed">20732968</ArticleId></ArticleIdList></Reference><Reference><Citation>Draper J, Subbiah S, Bailey R, et al. Murmur clinic: validation of a new model for detecting heart valve disease. Heart. 2019;105:56&#x2013;9. doi: 10.1136/heartjnl-2018-313393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2018-313393</ArticleId><ArticleId IdType="pmc">PMC6317436</ArticleId><ArticleId IdType="pubmed">30049836</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya S, Pavitt C, Lloyd G, et al. Provision, organization and models of heart valve clinics within The United Kingdom. QJM . 2015;108:113&#x2013;7. doi: 10.1093/qjmed/hcu164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcu164</ArticleId><ArticleId IdType="pubmed">25099608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahy IR, Dougall H, Buckley A, et al. Routine hospital based follow up for patients with mechanical valve prostheses: is it worthwhile? Heart. 1999;82:520&#x2013;2. doi: 10.1136/hrt.82.4.520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/hrt.82.4.520</ArticleId><ArticleId IdType="pmc">PMC1760272</ArticleId><ArticleId IdType="pubmed">10490572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood I, Kallingal J, Sabtu N, et al. Routine approach to follow-up and echocardiogram after a valve replacement surgery is not a clinically effective strategy. Heart. 2009;95:59.</Citation></Reference><Reference><Citation>Ionescu A, McKenzie C, Chambers JB. Are valve clinics a sound investment for the health service? A cost-effectiveness model and an automated tool for cost estimation. Open Heart. 2015;2:e000275. doi: 10.1136/openhrt-2015-000275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/openhrt-2015-000275</ArticleId><ArticleId IdType="pmc">PMC4636677</ArticleId><ArticleId IdType="pubmed">26568835</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulgheru R, Pibarot P, Sengupta PP, et al. Multimodality Imaging Strategies for the Assessment of Aortic Stenosis: Viewpoint of the Heart Valve Clinic International Database (HAVEC) Group. Circ Cardiovasc Imaging. 2016;9:e004352. doi: 10.1161/CIRCIMAGING.115.004352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCIMAGING.115.004352</ArticleId><ArticleId IdType="pubmed">26863917</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers J, Campbell B, Wilson J, et al. How should specialist competencies in heart valve disease be recognized? QJM . 2015;108:353&#x2013;4. doi: 10.1093/qjmed/hcv002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcv002</ArticleId><ArticleId IdType="pubmed">25609702</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe6;kke PS, J&#xf8;rgensen TH, Bieliauskas G, et al. Impact of Intensified Outpatient Follow-Up on Rehospitalization After Transcatheter Aortic Valve Implantation: Results From the HOSPITAVI Trial. Am J Cardiol. 2025;245:17&#x2013;24. doi: 10.1016/j.amjcard.2025.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2025.01.031</ArticleId><ArticleId IdType="pubmed">39900323</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank D, Durand E, Lauck S, et al. A streamlined pathway for transcatheter aortic valve implantation: the BENCHMARK study. Eur Heart J. 2024;45:1904&#x2013;16. doi: 10.1093/eurheartj/ehae147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae147</ArticleId><ArticleId IdType="pmc">PMC11143387</ArticleId><ArticleId IdType="pubmed">38554125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood DA, Lauck SB, Cairns JA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019;12:459&#x2013;69. doi: 10.1016/j.jcin.2018.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2018.12.020</ArticleId><ArticleId IdType="pubmed">30846085</ArticleId></ArticleIdList></Reference><Reference><Citation>Durand E, Beziau-Gasnier D, Michel M, et al. Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial. Eur Heart J. 2024;45:952&#x2013;62. doi: 10.1093/eurheartj/ehae081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehae081</ArticleId><ArticleId IdType="pubmed">38437633</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>